Phase I/III AFFINITY trial of rVIII-SingleChain (CSL Behring) shows good safety and efficacy for Haemophilia A
Pharmacokinetic results for the recombinant coagulation single-chain factor VIII rVIII-SingleChain, from CSL Behring, showed improved half-life over octocog alfa (the comparator) in patients with Haemophilia A. It also demonstrated a safety and efficacy profile that supports advancement to late-stage clinical development.
The AFFINITY Phase I/III study is an open-label, multi-center trial that examines the crossover safety, efficacy and pharmacokinetics of rVIII-SingleChain. The data were presented at the International Society on Thrombosis and Haemostasis (ISTH) congress.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
3 mins